Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Antimetabolite Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 5892-D

    Medicare Part B Step Therapy Antimetabolites

    Customize your policy alerts

    Sign up for zing_health Policy 5892-D alerts

    Get alerted when Policy 5892-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs preferred and non-preferred antimetabolite products for Medicare Part B members requesting treatment. Non-preferred products require prior authorization and are covered when specified clinical exception criteria are met.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Antimetabolites
    Policy CodePolicy 5892-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred generic pemetrexed before requesting non-preferred Alimta or Pemfexy unless a qualifying exception applies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1preferred antimetabolite product
    2non-preferred antimetabolite products
    365 daysprior-treatment lookback

    Non-Preferred Product Exception Criteria

    Non-preferred product exception criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage for a non-preferred product is provided when ANY of the following criteria is met.

    Qualifying exception

    • Prior treatment: Member has received treatment with the non-preferred product in the past 365 days.within the past 365 days
    • Intolerable adverse event: Member has had a documented intolerable adverse event to the preferred product, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.documented intolerable adverse event; not an expected active-ingredient adverse event

    Initial Non-Preferred Product Coverage

    Initial non-preferred product coverage

    A non-preferred product is covered when any one of the following exception criteria is met.

    Initial non-preferred product exception

    • Prior use: Member has received treatment with the non-preferred product in the past 365 days.past 365 days
    • Preferred product intolerance: Member has had a documented intolerable adverse event to the preferred product, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.documented intolerable adverse event

    Exception Review and Documentation Requirements

    Prior Authorization

    Exception Review and Prior Authorization

    Submit a prior authorization request for any non-preferred product. Coverage may be approved when clinical circumstances exclude use of the preferred product or when prior treatment supports a clinical exception; review is also subject to applicable NCDs, LCDs, and Medicare Part B utilization management programs.

    • This program applies to all members requesting treatment with a non-preferred product.
    • Preferred products may still require clinical prior authorization review.
    Step Therapy

    Preferred Pemetrexed First

    Use preferred generic pemetrexed first before requesting a non-preferred pemetrexed product, unless a qualifying clinical exception applies.

    • Preferred: pemetrexed (generic).
    • Non-preferred: Alimta (pemetrexed) and Pemfexy (pemetrexed).
    Documentation Required

    Document Prior Non-Preferred Product Use

    Document that the member received treatment with the requested non-preferred product within the applicable 365-day lookback period.

    • Include the product name and treatment history in the prior authorization submission.
    • Prior use of the non-preferred product within the past 365 days may support a clinical exception.
    Documentation Required

    Document Preferred Product Intolerance

    If requesting a non-preferred product because of intolerance to preferred pemetrexed, document an intolerable adverse event and establish that it was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

    • Identify the adverse event and its severity.
    • Explain why the event was intolerable and why it was not expected based on the prescribing information.
    Denial Risk

    Denial Risk: No Qualifying Exception

    A non-preferred product does not meet step-therapy exception criteria when there is no qualifying prior treatment and no documented intolerance-based exception. Requests lacking the required clinical documentation may be denied.

    • No treatment with the requested non-preferred product in the past 365 days.
    • No documented intolerable adverse event to preferred pemetrexed that was not an expected adverse event attributed to the active ingredient.
    • Coverage remains subject to applicable NCDs, LCDs, and Medicare Part B utilization management requirements.

    Preferred and Non-Preferred Products

    StepCoverage statusProduct(s)Requirement
    1PreferredPemetrexed (generic)Use first as the plan-preferred product.
    ExceptionNon-preferred; covered with criteriaAlimta (pemetrexed); Pemfexy (pemetrexed)Prior authorization is required. Coverage is provided when the member received the requested non-preferred product within the past 365 days, or had a documented intolerable adverse event to the preferred product that was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Antimetabolites
    Policy CodePolicy 5892-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred generic pemetrexed before requesting non-preferred Alimta or Pemfexy unless a qualifying exception applies.
    SourceLink
    On This Page
    Non-Preferred Product Exception CriteriaInitial Non-Preferred Product CoverageException Review and Documentation RequirementsPreferred and Non-Preferred Products